Multidrug resistance: Molecular and clinical aspects

Cytokines, Cellular and Molecular Therapy

Volumn 3, Issue 2, 1997, Pages 91-99

  Dicato, Mario ^a   Duhem, Caroline ^a   Pauly, Marc ^b   Ries, Fernand ^a  

^a CENTRE HOSPITALIER DE LUXEMBOURG   (Luxembourg)

^b UNIVERSITY OF LUXEMBOURG   (Luxembourg)

Author keywords

mdr gene family; Multidrug rresistance; P glycoprotein; Tumor aggressiveness

Indexed keywords

GENE PRODUCT; GLYCOPROTEIN GP 170; GLYCOPROTEIN P; MEMBRANE PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER CHEMOTHERAPY; CANCER GENETICS; CONTROLLED STUDY; GENE EXPRESSION; GENE FUSION; GENE STRUCTURE; HUMAN; HUMAN CELL; MOLECULAR EVOLUTION; MULTIDRUG RESISTANCE; MULTIDRUG RESISTANCE GENE; MULTIGENE FAMILY; PRIORITY JOURNAL; PROGNOSIS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS; CLONING, MOLECULAR; DRUG RESISTANCE, MULTIPLE; EVOLUTION; GENE EXPRESSION; GENES, MDR; HUMANS; MULTIGENE FAMILY; NEOPLASMS; P-GLYCOPROTEIN; PROGNOSIS;

EID: 0030749045     PISSN: 13684736     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (90)

1. Riordan JR, Deuchars K, Kartner N et al, Amplification of P-glycoprotein genes in multidrug-resistant mammalian cell lines. Nature (1985) 316: 817-19.
2. Gros P, Croop J, Housman D, Mammalian multidrug resistance gene: complete cDNA sequence indicates strong homology to bacterial transport proteins. Cell (1986) 47: 371-80.
3. Chen CJ, Chin JE, Ueda K et al, Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell (1986) 47: 381-9.
4. Roninson IB, Chin JE, Choi K et al, Isolation of human mdr DNA sequences amplified in multidrug-resistant KB carcinoma cells. Proc Natl Acad Sci USA (1986) 83: 4538-42.
5. Chin JE, Soffir R, Noonan KE et al, Structure and expression of the human mdr (P-glycoprotein) gene family. Mol Cell Biol (1989) 9: 3808-20.
6. Callen DF, Baker E, Simmers RN et al, Localization of the human multiple drug resistance gene, MDR1, to 7q21.1. Hum Genet (1987) 77: 142-4.
7. Chen CJ, Chin JE, Ueda K et al, Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell (1986) 47: 381-9.
8. Chen CJ, Clark D, Ueda K et al, Genomic organization of the human multidrug resistance (MDR1) gene and origin of P-glycoproteins. J Biol Chem (1990) 265: 506-14.
9. Ling V, P-glycoprotein and resistance to anticancer drugs. Cancer (1992) 69: 2603-9.
10. Arecli RJ, Clinical significance of P-glycoprotein in multidrug resistance malignancies. Blood (1993) 81: 2215-22.
11. Van Kallen EK, Pinedo HM, Giaccone G, Multidrug resistance from the clinical point of view. Eur J Cancer (1991) 27: 1481-6.
12. Nooter K, Sonneveld P, Clinical relevance of P-glycoprotein expression in haematological malignancies. Leuk Res (1994) 17: 233-43.
13. Pinedo HM, Giaccone G, P-glycoprotein: a marker of cancer cell behaviour. N Engl J Med (1995) 333: 1417-19.
14. Shen DW, Fojo A, Roninson IB et al, Multidrug resistance of DNA-mediated transformants is linked to transfer of the human mdr1 gene. Mol Cell Biol (1986) 6: 4039-44.
15. Ueda K, Cardarelli C, Gottesman MM, Pastan I, Expression of a full-length cDNA for the human 'MDR1' gene confers resistance to colchicine, doxorubicin, and vinblastine. Proc Natl Adac Sci USA (1987) 84: 3004-8.
16. Bauard M, Pastan I, Gottesman MM, Transfer of the mdr1 gene into hematopoietic cells. Eur J Cancer (1996) 32A: 1019-23.
17. Podda S, Ward M, Himelstein A et al, Transfer and expression of the human multiple drug resistance gene into live mice. Proc Natl Acad Sci USA (1992) 89: 9676-80.
18. Lincke CR, Smith JJM, Van der Velde-Koerts T, Borst P, Structure of the human mdr3 gene and physical mapping of the human mdr locus. J Biol Chem (1991) 266: 5303-10.
19. Ueda K, Pastan I, Gottesman MM, Isolation and sequence of the promoter region of the human multidrug-resistance (P-glycoprotein) gene. J Biol Chem (1987) 262: 17432-6.
20. Cornwell MM, The human multidrug resistance gene: sequences upstream and downstream of the initiation site influence transcription. Cell Growth Diff (1990) 1: 607-15.
21. Madden MJ, Morrow CS, Nakagawa M et al, Identification of 5′ and 3′ sequences involved in the regulation of transcription of the human mdr1 gene in vivo. J Biol Chem (1993) 268: 8290-7.
22. Van groenigen M, Valentijn LJ, Baas F, Identification of a functional initiator sequence in the human mdr1 promoter. Biochim Biophys Acta (1993) 1172: 138-46.
23. Kohno K, Sato SI, Uchiumi T et al, Tissue-specific enhancer of the human multidrug-resistance (MDR1) gene. J Biol Chem (1990) 265: 19690-6.
24. Germann LIA, P-glycoprotein - a mediator of multidrug resistance in tumor cells. Eur J cancer (1996) 32A: 927-44.
25. Choi K, Chen CJ, Kriegler M, Roninson IB, An altered pattern of cross-resistance in multidrug-resiatant human cells results from spontaneous mutations in the mdr1 (P-glycoprotein) gene. Cell (1988) 53: 519-29.
26. Safa AR, Stern RK, Choi K et al, Molecular basis of preferential resistance to colchicine in multidrug-resistant human cells conferred by Gly-185-Val-185 substitution in P-glycoprotein. Proc Natl Acad Sci USA (1990) 87: 7225-9.
27. Fojo AT, Ueda K, Slamon DJ et al, Expression of a multidrug-resistance gene in human tumors and tissues. Proc Natl Acad Sci USA (1987) 84: 265-9.
28. Scotto KW, Biedler JL, Melera PW, Amplification and expression of genes associated with multidrug resistance in mammalian cells. Science (1986) 232: 751-5.
29. Shen DW, Fojo A, Chin JE et al, Human multidrug-resistant cell lines: increased mdr1 expression can precede gene amplification. Science (1986) 232: 643-5.
30. Kohno K, Sato S, Takano H et al. The direct activation of human mutidrug resistance gene (mdr1) by anticancer agents. Biochem Biophys Commun (1989) 165: 1415-21.
31. Nguyen KT, Liu B, Ueda K et al, Transactivation of the human multidrug resistance (mdr1) gene promoter by p53 mutants. Oncol Res (1994) 6: 71-7.
32. Stark GR, Debatisse M, Giulotto E, Wahl GM, Recent progress in understanding mechanisms of mammalian DNA amplification. Cell (1989) 57: 901-8.
33. Pauly M, Kayser I, Schmitz M et al, The human mdr1 (multidrug resistance) gene harbours a long homopyrimidine homopurine sequence next to a cluster of Alu repeated sequences in intron 14. Gene (1995) 153: 299-300.
34. Pauly M, Kayser I, Schmitz M et al, Repetitive DNA sequences located in the central region of the human mdr1 (multidrug resistance) gene may account for a gene fusion event during its evolution. J Mol Evol (1995) 41: 974-8.
35. Kartner N, Rierder JR, Ling V, Cell surface P-glycoprotein is associated with multidrug resistance in mammalian cells. Science (1983) 221: 1285-8.
36. Pauly M, Ries F, Dicato M, The genetic basis of multidrug resistance. Pathol Res Practice (1992) 188: 804-7.
37. Goldie JH, Goldman AJ, A mathematical model for relating the drug sensitivity to the spontaneous mutation rate. Cancer Treat Rep (1979) 63: 1727-33.
38. Cole SPC, Bhardwaj G, Gerlach JH, Overexpression of a transporter gene multidrug resistant human lung cancer cell line. Science (1992) 258: 1650-4.
39. Zaman GJR, Flens MJ, Van Leusden MR, The human multidrug resistance associated protein MRP id a plasma membrane drug-efflux pump. Proc Natl Acad Sci USA (1994) 91: 8822-6.
40. Kruh GD, Caughan KT, Godwin A, Chan A, Expression pattern of MRP in human tissues and adult solid tumor cell lines. J Natl Cancer Inst (1995) 87: 1256-9.
41. Scheper RJ, Broxterman HJ, Scheffer GL, Overexpression of a MR 110,000 vesicle protein in non-P-glycoprotein mediated multidrug resistance. Cancer Res (1993) 53: 1475-9.
42. Scheffer GL, Wijngaard PL, Flens MJ et al. The drug resistance-related protein LRP is the major human vaults protein. Nature Med (1995) 1: 578-82.
43. Izquierdo MA, Van der Zee AGJ, Vermorken JB et al, Drug resistance-associated marker Lrp for prediction of response to chemotherapy and prognosis in advanced ovarian carcinoma. J Nad Cancer Inst (1995) 87: 1230-6.
44. Yuen AR, Sikic BI, Multidrug resistance in lymphomas. J Clin Oncol (1994) 12: 2453-9.
45. Chaudhaary PM, Mechetner EB, Robinson IB, Expression and activity of the multidrug resistance P-glycoprotein in human peripheral blood lymphocytes. Blood (1992) 80: 2735-9.
46. Chaudhary PM, Robinson IB, Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. Cell (1991) 66: 85-94.
47. Sato H, Gottesman MM, Goldstein LJ et al, Expression of the multidrug resistance gene in myeloid leukemias. Leuk Res (1990) 14: 11-22.
48. Pirker R, Wallner T, Geissler K et al, MDR1 gene expression and treatment outcome in acute myeloid leukemia. J Natl Cancer Inst (1991) 83: 708-12.
49. Veerman AJP, Kaspers GJL, Pieters R, Cellular drug resistance in childhood leukemia. Ann Hematol (1994) 69: S31-4.
50. Goasguen JE, Dossot JM, Fardel O et al, Expression of the multidrug associated P-glycoprotein (P-170) in 59 cases of de novo acute lymphoblastic leukemia. Prognostic implications. Blood (1993) 81: 2394-9.
51. Pieters R, Hongo T, Loonen AH et al, Non P-glycoprotein mediated multidrug resistance in children with relapsed acute lymphoblastic leukemia. Br J Cancer (1992) 65: 691-7.
52. Pirker R, Goldstein LJ, Ludwig H, Expression of multidrug resistance gene in blast crisis of chronic myelogenous leukemia. Cancer Commun (1989) 1: 141-4.
53. Turkina AG, Baryshnikov AY, Sedyakaina NP et al, Studies of P-glycoprotein in chronic myelogenous leukemia patients: expression, activity and correlations with CD34 antigens. Br J Haematol (1996) 92: 88-96.
54. Epstein J, Xoao H, Koba B, P-glycoprotein expression in plasma cell myeloma is associated with resistance to VAD. Blood (1989) 74: 913-17.
55. Sonneveld P, Durie BGM, Lokhorst HM et al, Modulation of multidrug resistant multiple myeloma by cyclosporin. The Leukemia Group of the EORTC and the HOVON. Lancet (1992) 340: 255-9.
56. Dalton WS, Crowley JJ, Salmon S et al, A phase III randomized study of oral verapamil as a chemosensitizer to reverse drug resistance in patients with refractory myeloma: a Southwest Oncology Group Study. Cancer (1995) 75: 815-20.
57. Chabner BA, Bates SE, Fojo At et al. Drug resistance in adult lymphomas. Semin Hematol (1994) 31: 70-87.
58. Miller TP, Grogan TM, Dalton WS et al, P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high dose varapamil. J Clin Oncol (1991) 9: 17-24.
59. Cheng AL, Su IJ, Chen YC, Wang CH, Expression of P-glycoprotein and glutathione-S-transferase in recurrent lymphomas: the possible role of Epstein-Barr virus, immunophenotypes and other predisposing factors. J Clin Oncol (1993) 11: 109-15.
60. Rodriguez C, Commes T, Robert J, Rossi JF, expression of P-glycoprotein and anionic glutathione-S-transferase genes in non-Hodgkin's lymphoma. Leuk Res (1993) 17: 149-56.
61. Pileris S, Sabattini E, Falini B, Immunohistochemical detection of the multidrug transport protein P-170 in human normal tissues and malignant lymphomas. Histopathology (1991) 19: 131-40.
62. Niehans GA, Jaszez W, brunetta V et al, Immunohistochemical identification of P-glycoprotein in previously untreated, diffuse large cell and immunoblastic lymphomas. Cancer Res (1992) 52: 3768-75.
63. Gascoyne R, Hoskins P, Connors J et al, A study of clinical and pathologic variables affecting disease specific survival (DSS) of patients with diffuse large cell lymphoma treated with MACOP-B or VACOP-B: univariate and multyivariate analysis. Proc Am Soc Clin Oncol (1994) 13: 374 (abstr).
64. Kruh GD, Goldstein LJ, Doxorubicin and multidrug resistance. Curr Opin Oncol (1993) 5: 1029-34.
65. Verelle P, Meissonier F, Fonck Y, Clinical relevance of immunohistochemical detection of multidrug resistance P-glycoprotein in breast carcinoma. J Natl Cancer Inst (1991) 83: 111-16.
66. Giaccone G, Linn SC, Pinedo HM, Multidrug resistance in breast cancer: mechanisms, strategies. Eur J Cancer (1995) 31A(S7): S15-17.
67. Linn SC, Van Ark-Ott J, Kuiper K, Expression of multidrug resistance (MDR) genes in primary breast cancer and in advanced anthracycline-resistant breast cancer patients undergoing taxol treatment. Proc AACR (1994) 35: 207.
68. Chan HSL, Thorner PS, Haddad G, Ling V, Immunohistochemical detection of P-glycoprotein: prognostic correlation in soft tissue sarcoma of childhood. J Clin Oncol (1990) 8: 689-704.
69. Stein V, Wunderlich V, Haensch W, Schmich-Peter P, Expression of the mdr1 gene in bone and soft tissue sarcomas of adult patients. Eur J Cancer (1993) 29A: 1979-81.
70. Baldini N, Scotlandi K, Barbanti-Brodano G et al, Expression of P-glycoprotein in high-grade osteosarcomas in relation to clinical outcome. N Engl J Med (1995) 333: 1380-5.
71. Linn SC, Gaiccone G, MDR1/P-glycoprotein expression in colon cancer. Eur J Cancer (1995) 31 A: 1291-4.
72. Weinstein RS, Jakati SM, Dominguez JM et al, Relationship of the expression of the multidrug resistance gene product (P-glycoprotein) in human colon carcinoma to local tumor aggressiveness and lymph node metastasis. Cancer Res (1991) 51: 2720-6.
73. Goldstein LJ, Fojo AAT, Nesa K, Expression of the multidrug resistance mdr1 gene in neuroblastoma. J Clin Oncol (1990) 8: 128-36.
74. Favrot M, Combaret V, Goillet E, Expression of P-glycoprotein restricted to normal cells in neuroblastoma biopsies. Br J Cancer (1991) 64: 233-8.
75. Chan HSL, Haddad G, Thorner RS et al, P-glycoprotein expression as a predictor of outcome therapy for neuroblastoma. N Engl J Med (1991) 325: 1608-14.
76. Norris MD, Bordow SB, Marshall GM et al, Expression of the gene for multidrug resistance-associated protein and outcome in patients with neuroblastoma. N Engl J Med (1996) 334: 231-8.
77. Duhem C, Ries F, Dicato M, What does mutidrug resistance (MDR) expression mean in the clinic? The Oncologist (1996) 1: 151-8.
78. Markman M, Chemosensitivity and chemoresistance assays: are they clinically relevant? J Cancer Res Clin Oncol (1995) 121: 441-2.
79. Tsuro T, Iida M, Tsukogoshi S, Sakurai Y, Overcoming of vincristine resistance in P-388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res (1981) 41: 1967-72.
80. Ries F, Dicato M, Treatment of advanced breast cancer with doxorubicin, vincristine and continuous infusion of verapamil. A phase I-II clinical trial. Med Oncol Tumor Pharmacother (1991) 9: 39-42.
81. Chabner BA, Reversal of multidrug resistance. J Clin Oncol (1991) 9: 4-6.
82. Raderer M, Scheithaner W, Clinical trials of agents that reverse multidrug resistance. A literature review. Cancer (1993) 72: 3553-63.
83. Mulder HS, Pinedo HM, Timmer AT et al, Multidrug resistance modifying components in human plasma with potential clinical significance. J Exp Ther Oncol (1996) 1: 19-28.
84. Fischer GA, Sikie BI, Clinical studies with modulators of multidrug resistance. Hematol Oncol Clin North Am (1995) 9: 363-82.
85. Wishart GC, Bisset D, Paul J, et al, Quinidine as a resistance modulator of epirubicin in advanced breast cancer: mature results of a placebo-controlled randomized trial. J Clin Oncol (1994) 9: 1771-7.
86. Egorin M, Fracasso P, Zuhowski E et al, Effect of MDR modulator, SDZ PSC833 on the pharmacokinetics and pharmacodynamics of 3 M paclitaxel infusion. Proc Am Soc Clin Oncol (1996) 15: 473.
87. Beketic-Orèskovic L, Duran GE, Chen G et al, Decreased mutation rate for cellular resistance to doxorubicin and suppression of MDR1 gene activation by the cyclosporin PCS 833. J Natl Cancer Inst (1995) 1593-602.88. Beck WT, Circumvention of multidrug resistance with anti- P-glycoprotein antibodies: clinical potential or experimental artifact. J Natl Cancer Inst (1995) 87: 73-5.
88. Beketic-Orèskovic L, Duran GE, Chen G et al, Decreased mutation rate for cellular resistance to doxorubicin and suppression of MDR1 gene activation by the cyclosporin PCS 833. J Natl Cancer Inst (1995) 1593-602.88. Beck WT, Circumvention of multidrug resistance with anti- P-glycoprotein antibodies: clinical potential or experimental artifact. J Natl Cancer Inst (1995) 87: 73-5.
89. Beck WT, Circumvention of multidrug resistance with anti-P-glycoprotein antibodies: clinical potential or experimental artifact. J Natl Cancer Inst (1995) 87: 73-5.
90. Gersmann UA, Harding MW, Chemosensitizers to overcome and prevent multidrug resistance? J Natl Cancer Inst (1995) 87: 1573-5.